Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Journal of Environmental Pathology, Toxicology and Oncology
Factor de Impacto: 1.625 Factor de Impacto de 5 años: 1.63 SJR: 0.402 SNIP: 0.613 CiteScore™: 2.3

ISSN Imprimir: 0731-8898
ISSN En Línea: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2016012256
pages 355-364

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy

Vidhula Ahire
LARIA, iRCM, François Jacob Institute, DRF-CEA, Caen, France; UMR6252 CIMAP, CEA - CNRS– ENSICAEN, Université de Caen Normandie, Caen, France
D. Das
Department of Biotechnology, Siddhaganga Institute, Tumkur
Kaushala Prasad Mishra
Department of Life Sciences, University of Mumbai, Mumbai, India; Nehru Gram Bharati University, Allahabad, UP, India; Foundation for Education and Research, India and BM International Research Centre, Mumbai, India
G. R. Kulkarni
School of Basic Medical Science, University of Pune, Pune- 411007, India
L. Ackland
Centre for Cellular & Molecular Biology, School of Life and Environmental Sciences, Deakin University, Australia

SINOPSIS

Y220C, a substitution mutation in p53, causes major structural changes in the protein and is known to form a new protein cavity. This cavity is reckoned to accommodate small drug candidates that may play a key role in cancer treatment. Present study was aimed at determining a drug candidate that could inhibit the mutant p53 based on structural drug rationale. Docking of mutated p53 was performed to determine the drug of choice from the derivatives of 1-hydroxy-2- methylanthraquinone exhibiting anti-cancer properties. The cavity had been tested for identification of an accurate position vector for molecular docking studies using structure based drug design. The docked structure was validated using discovery studio 3.5. The best choice of two molecules were obtained by docking in specific solvent for 6 nanoseconds at a temperature of 310 K. Out of a library of compounds, acetamido-2-carboxy-4-dimethylamino-2- hydroxybenzophenone satisfied the ADMET and was found to be a potential target for mutant p53. This ligand binds at the active site of the protein. Results of present study offer a rationale of the lead ligands that can rescue oncogenic p53 by targeting the mutation site. Therefore, it is suggestive that small molecules may serve as an effective and novel anti-cancer drug.


Articles with similar content:

Role of c-MET in Upper Aerodigestive Malignancies — From Biology to Novel Therapies
Journal of Environmental Pathology, Toxicology and Oncology, Vol.24, 2005, issue 3
Radha Uppalapati, Tanguy Y. Seiwert, Sascha Dietrich, Patrick C. Ma
Perspectives on c-Myc, Cyclin D1, and Their Interaction in Cancer Formation, Progression, and Response to Chemotherapy
Critical Reviews™ in Oncogenesis, Vol.13, 2007, issue 2
Jack Wu, Fazlul H. Sarkar, D. Joshua Liao, Hector Biliran, Archana Thakur
Regulation of the Cancer Stem Cell Phenotype by Raf Kinase Inhibitor Protein via Its Association with Kruppel-Like Factor 4
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Stephanie Wottrich , Benjamin Bonavida
Differential Modifying Effects of Food Additive Butylated Hydroxytoluene Toward Radiation and 4-Nitro-quinoline 1-Oxide−Induced Genotoxicity in Yeast
Journal of Environmental Pathology, Toxicology and Oncology, Vol.30, 2011, issue 3
Nagesh N. Bhat, Kapil B. Shirsath, B. Sreedevi, Kshiti B. Anjaria
Dual Roles of Kruppel-Like Factor 4 as a Tumor Suppressor or Oncogene
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
Peng-Sheng Zheng, Wen-Ting Yang